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Abstract
The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first 
time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-
Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongo-
ing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a 
global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, 
several clinical and sub-clinical studies are currently undertaken to find a gold-standard therapeutic regimen with high effi-
cacy and low side effect. Based on the published scientific evidence published to date, we summarized herein the effects of 
different potential therapies and up-to-date clinical trials. The review is intended to help readers aware of potentially effective 
COVID-19 treatment and provide useful references for future studies.
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Introduction
In the first two decades of the twenty-first century alone, 
three pandemic infectious diseases caused by the human cor-
onaviruses (CoVs) have emerged: Severe Acute Respiratory 
Syndrome Coronavirus-1 (SARS-CoV1), Middle East Res-
piratory Syndrome coronavirus (MERS-CoV), and the now, 
a novel coronavirus (SARS-CoV2 or nCoV-19). In the latter 
case, the outbreak was identified first in December 2019 
in Wuhan city, the capital of Hubei Province, China [1–3]. 
The transmission rate of nCoV-19 in humans appears to be 
higher than SARS-CoV1 and MERS-CoV [4]. The Corona-
viridae Study Group (CSG) of the International Commit-
tee on Taxonomy of Viruses (ICTV) renamed nCoV-19 as 
SARS-CoV2 [5], while the disease was named by the World 
Health Organization (WHO) as Coronavirus Disease-2019 
(COVID-19) [6]. Based on the latest WHO report, the num-
ber of SARS-CoV2 cases (over 6.4 million globally with 
more than 379 thousand mortalities, updated on 2 June 
2020) will undoubtedly be counted by the millions.
Structurally, coronaviruses have a positive-sense RNA 
genome with 26–32 kb range in length which is surrounded 
by nucleocapsid and envelope [6]. Two-thirds of the viral 
RNA is mainly located in the first open-reading frame 
(ORF), including ORF1a/b, and translates pp1a and pp1ab 
polyproteins, and also encodes different non-structural pro-
teins (NSP), which are key enzymes in the viral life cycle [7, 
8]. Several accessory proteins, which interfere with the host 
innate immune response, and also four essential structural 
proteins, including spike (S) glycoprotein, small envelope 
(E) protein, matrix (M) protein, and nucleocapsid (N) pro-
tein are encoded by remaining ORFs [9]. Protein structural 
analyses and molecular modeling studies suggest that key 
drug-binding pockets in the viral enzymes are probably con-
served across SARS-CoV2, SARS-CoV1, and MERS [10]. 
Accordingly, these tools can help to find anti-viral drugs 
against SARS-CoV2 with high specificity and lower side 
effects [11].
Via the S protein attachment to the host cells receptor, 
such as angiotensin-converting enzyme 2 (ACE2), SARS-
CoV2 may pass through the mucous membranes of the upper 
respiratory tract and enters the lungs. The most common 
symptoms which have been observed in several patients are 
fever and dry cough [11, 12]. Moreover, viral entrance to 
the peripheral blood from the lungs and viremia may occur. 
Then, the viral invasion could target organs that express 
ACE2, such as the lungs, gastrointestinal tract, heart, renal, 
and brain [13, 14].
The white blood cell (WBC) count in the early stage of 
the pathogenic process by SARS-CoV2 is generally normal 
or maybe slightly decreased [12], and most patients have 
lymphopenia [15]. Besides, the pro-inflammatory factors 
are significantly increased, which can aggravate the disease 
around 7–14 days after onset [16]. Most of the severely ill 
patients with SARS-CoV2 infection exhibit pneumonia 
(often called novel coronavirus infected pneumonia, NCIP) 
which may be associated with cytokine storm or Cytokines 
Release Syndrome (CRS): an imbalance between pro-inflam-
matory and anti-inflammatory factors. This life-threatening 
condition resulting from host immune dysfunction can lead 
to acute respiratory distress syndrome (ARDS) [17, 18]. The 
massive infiltration of neutrophils, monocytes, and lympho-
cytes has occurred in this severe type of acute lung injury. 
Most patients who suffer ARDS have diffuse bilateral edema 
accompanied by reduced lung compliance, alveolar damage, 
and bronchoalveolar lumen hyaline deposition which result 
in hypoxic respiratory failure [19].
According to the Diagnosis and Treatment of Pneumo-
nia Caused by SARS-CoV2 (updated to version 6), issued 
by the National Health Commission of the People’s Repub-
lic of China, and due to the lack of specific anti-viral ther-
apy against SARS-CoV2, current treatments have mainly 
focused on symptomatic and respiratory support [20].
Potential anti-COVID-19 therapy can be envisaged based 
on either direct effect on the coronavirus itself and/or on the 
immunotherapy options. One attractive approach is targeting 
receptor proteins on host cell surfaces that are often exploited 
by coronaviruses to bind via their receptor-binding domain 
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(RBD). Blocking such virus binding to deny viral entry 
to human cells is, thus, an attractive therapeutic approach 
[21, 22]. Besides, some therapeutic agents could effectively 
suppress viral replication by inhibiting the RNA-dependent 
RNA polymerase (RdRp). Considering the critical role of 
the innate immune response to coronavirus infection [23], 
blocking the signaling pathways involved in viral replica-
tion and self-assembly processes and production of virulence 
factors to restore the host’s innate immunity are reasonable 
anti-viral approaches. Some related target proteins include 
RdRp, helicase, N-terminal RNA-binding domain (NRBD), 
C-terminal RNA-binding domain (CRBD), different non-
structural proteins such as Nsp3 (Nsp3b, Nsp3c, PLpro, and 
Nsp3e) and Nsp7-Nsp8 complex, 3CLpro, E-channel (E pro-
tein), Spike (S), and ACE2 [11].
Up to date, the intermediate host of SARS-CoV2 is still 
unknown, and effective prophylactics or therapeutics are not 
available to treat SARS-CoV2 infection. Some therapeutic 
agents are used off-label, alone or in combination, but we 
need further experimental data and validation to achieve a 
gold-standard therapeutic regimen with high efficacy and 
low side effect. In this review, the effects of different thera-
pies on SARS-CoV2 with updated clinical trials (up to June 
2020) are assessed. Different drugs against COVID-19 are 
classified according to the certain or probable mechanism 
of actions (Fig. 1), including inhibitors of viral replica-
tion, inhibitors of viral proteases, inhibitors of viral entry 
to the host cell, immunoenhancement, immunomodulating, 
immunosuppressive, anti-inflammatory, pulmonary vaso-
effectors, and some anti-asthma/anti-tuberculosis drugs 
(Table 1). Overviews of several SARS-CoV2 clinical trials 
Fig. 1  The mechanism of actions of different drugs against COVID-
19. The figure illustrates the probable site of drugs effect during 
SARS-CoV2 infection including (1) binding and viral entry via 
membrane fusion or endocytosis (which are blocked by rhACE2, 
Bromhexine, Arbidol, Hydroxychloroquine, Ruxolitinib, and Barici-
tinib), (2) release of the viral genome, (3) translation of viral poly-
merase protein, (4) RNA replication, (5) genomic replication (which 
is inhibited by Oseltamivir and Emtricitabine), (6) translation of 
viral structural protein such as main proteases (which is inhibited by 
Atazanavir, Lopinavir, Darunavir, Danoprevir, and Noscapine), (7) 
capsidation and RNA-dependent RNA polymerase (which is inhib-
ited by Remdesivir, Favipiravir, and Ribavirin), (8) formation of 
the mature virion, (9) exocytosis. Other recommended drugs act on 
immune responses such as Tocilizumab and Siltuximab (via inhibi-
tion of IL-6), interferon-alpha, and beta (as the immunoenhancement 
agents), Fingolimod and Thalidomide (as the immunomodulating 
agents). The figure is “Created with BioRender.com”
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on previously approved drugs for the treatment of other viral 





The nucleoside analog, ribavirin (Virasol), is an anti-viral 
drug with broad-spectrum activity that is used for treat-
ing hepatitis C, respiratory syncytial virus, and some viral 
hemorrhagic fevers (e.g., Lassa) [24, 25]. It had several 
mechanisms recognized by which ribavirin exerts its anti-
viral action, including lethal mutagenesis, chain termina-
tion as specific or nonspecific, and inhibition of nucleotide 
biosynthesis to target RNA viruses [26]. The desire-specific 
mechanism of ribavirin action has not been fully understood 
[27]. Also, it is a “broad-spectrum” drug and cannot kill 
coronaviruses in a targeted manner [11]. The proposed 
mechanism of action of ribavirin in SARS-CoV2 is through 
inhibition of synthesis of viral RNA and capping of mRNA 
[28]. The anti-viral activity of ribavirin against animal CoVs 
and SARS-CoV1 has been shown although its effective-
ness along with interferon on MERS-CoV is contradictory. 
While several studies have shown the efficacy of ribavirin 
and interferon on their own [23, 29, 30], a combination of 
these drugs did not show positive outcomes in critically ill 
MERS patients [31, 32]. The efficacy of ribavirin mostly as 
combination therapy was assessed. The successful responses 
to ribavirin monotherapy and or combination therapy have 
been reported in several case report studies [33–37]. A mul-
ticenter, prospective, open-label, randomized, phase II trial 
was conducted in COVID-19 patients in Hong Kong. In the 
control group, the patients received lopinavir 400 mg and 
ritonavir 100 mg every 12 h for 14 days and the combina-
tion group received lopinavir 400 mg and ritonavir 100 mg 
every 12 h, ribavirin 400 mg every 12 h, and three doses of 
8 million international units of interferon β-1b for 14 days. 
This combination therapy was well tolerated and reduced 
the time to negative nasopharyngeal swab and hospital stay 
in patients with mild to moderate COVID-19 [38]. Also, 
an open-labeled, single-center, prospective, randomized, 
and controlled clinical trial is performed to investigate the 
efficacy and safety of different anti-viral regimens (Riba-
virin + Interferon α-1b, lopinavir/ritonavir + IFN α-1b, and 
Ribavirin + lopinavir/ritonavir + IFN α-1b) on 108 COVID-
19 patients. The results of this study can be helpful to pro-
vide obvious evidence for use of these regimens in the man-
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It is also worth noting that ribavirin had several known 
adverse effects such as hemolytic anemia, hypocalcemia, and 
hypomagnesemia [40]. It is also contraindicated to autoim-
mune hepatitis, hemoglobin disorder, kidney failure, preg-
nant females or males with pregnant partners, and those with 
hypersensitivities to it [26]. Because of inconsistent benefit 
with ribavirin for COVID-19 and its substantial safety con-
cerns, and very low quality of evidence, current data do not 
justify its use for the treatment of COVID-19. It seems that 
combination therapy is likely to provide the best chance for 
clinical efficacy. Therefore, extensive randomized controlled 
clinical trials are needed to confirm its efficacy on the mor-
tality, virological and clinical outcomes of COVID-19. The 
effect of ribavirin in combination with other treatments is 
being evaluated in eight clinical trials (Table 2).
Remdesivir
Remdesivir (RDV), GS-5734, is a monophosphorami-
date prodrug and adenosine nucleoside analog which is 
metabolized into active form GS-441524. The active form 
can reduce viral RNA production by acting on viral RNA 
polymerase [41]. RDV functioned at the stage of post-virus 
entry, which is in agreement with its putative anti-viral 
mechanism as a nucleotide analog [42]. It was developed 
by Gilead Sciences in 2017 for the treatment of Ebola virus 
infection but it is also used to treat Marburg virus, MERS, 
and SARS-CoV1 [41]. The RDV activity against many other 
human and zoonotic coronaviruses, including HCoV-NL63, 
HCoVOC43, HCoV-229E, mouse hepatitis beta coronavirus 
(MHV), bat beta coronaviruses HKU5, WIV1, and SHC014, 
and porcine delta coronavirus, was also observed [43–45]. 
Therefore, it can be introduced as a treatment choice for 
SARS-CoV2 [46].
The effect of RDV on SARS-CoV1 and MERS-CoV 
in human airway epithelial (HAE) cells was investigated 
and the reduced viral titers were observed, time-depend-
ently [47]. Based on these observations, the expected role 
of GS-5734 in the SARS-CoV2 has been presented [48]. 
The obtained  EC50 of RDV against SARS-CoV2 was 
0.77 μmol/L using an in vitro study [49]. Based on molec-
ular docking data, some viral proteins including RdRp, 
Nsp3b, E-channel, and TMPRSS2 were identified as poten-
tial targets for RDV [11]. RDV is currently undergoing a 
randomized, double-blind, controlled phase III clinical trial 
study in China. Moreover, for evaluating the efficacy and 
safety of RDV in patients with SARS-CoV2 pneumonia, two 
multicenter randomized, double-blind, placebo-controlled, 
Phase III studies were launched in February 2020 in China 
[50].
Two clinical trials of RDV have been implemented in 
China and this agent is the first investigational therapeu-
tic which was approved by the FDA [42]. Despite the first 
reported case of SARS-CoV2 in the US used intravenous 
(IV) RDV on day 7 and achieved good results, the effective-
ness of RDV is still questioned [51, 52]. Animal experi-
ments indicated that both prophylactic and therapeutic RDV 
vs. lopinavir–ritonavir combination has effectively superior 
anti-viral effect in lung tissues, and lung function improve-
ment [53]. Because of its promising results in SARS-CoV2 
patients, RDV has now entered into phase III clinical trials 
[49].
According to the RDV activity against SARS-CoV2 in 
pre-clinical studies, a randomized and double-blind clini-
cal trial study is ongoing to evaluate the RDV safety and 
effectiveness in 308 hospitalized patients with mild/moder-
ate SARS-CoV2 pneumonia (NCT04252664) [54]. Another 
ongoing multicenter, double-blind, placebo-controlled, and 
phase III randomized clinical study has evaluated the RDV 
safety and efficacy in 453 hospitalized adult patients with 
severe SARS-CoV2 respiratory disease (NCT04257656) 
[55]. The details of the two trials are summarized in Table 2 
[56].
By March 6, 2020, another Phase III randomized study 
was started to evaluate the RDV anti-viral activity and its 
safety in participants with severe SARS-CoV2. In this study, 
four arms including experimental and control groups are 
evaluated (NCT04315948) [57]. Another randomized, open-
label, phase III trial study was performed on 397 patients 
with severe COVID-19 who received 200 mg of remdesi-
vir on day 1 and 100 mg once daily on subsequent days 
(NCT04292899) [58]. The results of this trial did not show 
a significant difference between a 5-day course and a 10-day 
course of remdesivir. Because of the lack of placebo control 
in this trial, it is not a test of the efficacy of remdesivir [59].
Favipiravir
Favipiravir (T-705) is an anti-viral drug that strongly inhib-
its RNA polymerases of RNA viruses. The mechanism of 
action is related to inhibition of transcription and replication 
of viral genes which eventually leads to the prevention of the 
viral RNA synthesis within infected cells [60]. Favipiravir 
has been shown to display anti-viral effects against many 
RNA viruses such as resistant influenza virus, arenaviruses, 
bunyaviruses, filoviruses, Rift Valley Fever, Yellow Fever, 
West Nile, Western equine encephalitis, foot-and-mouth dis-
ease virus, norovirus and avian influenza [61–65]. Because 
of its broad-spectrum anti-viral coverage, favipiravir was 
evaluated in the treatment of Ebola virus, Lassa virus, han-
tavirus, and now SARS-CoV2 [33, 66–68]. The efficacy of 
favipiravir versus LPV/r in SARS-CoV2 was evaluated in an 
open-label non-randomized control study in China. Changes 
in chest CT, viral clearance, and drug safety were surveyed 
in two groups of patients. The results showed a shorter viral 
clearance time, significant improvement in chest imaging, 
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and fewer adverse effects in the favipiravir group compared 
to the control group [69]. In a randomized clinical trial, the 
efficacy and safety of favipiravir and arbidol were evaluated 
in 240 SARS-CoV2 patients. It was shown that the clini-
cal recovery rate was higher in the favipiravir group. The 
time of fever reduction and cough relief in the favipiravir 
group was notably shorter than that in the arbidol group. But 
some anti-viral-associated adverse effects such as abnormal 
liver function tests, psychiatric symptom reactions, digestive 
tract reactions and raised serum uric acid were higher in the 
favipiravir group [70]. To evaluate the beneficial effects of 
favipiravir in coronavirus disease, several clinical trials on 
its efficacy are ongoing. The registered clinical trials have 
been reported and shown in Table 2.
Emtricitabine/tenofovir
Tenofovir is a DNA synthesis inhibitor and approved as a 
human immunodeficiency virus (HIV) reverse transcriptase 
inhibitor. It has been suggested that tenofovir could be a 
potential drug candidate for SARS-CoV2 pulmonary dis-
ease, although the clinical effectiveness of this drug has not 
yet been evidenced for SARS-CoV2 [71]. At the time of 
preparing this manuscript, there was only one clinical trial 
that was designed to investigate the effectiveness of emtric-
itabine (FTC)/tenofovir alafenamide fumarate tablets (TAF) 
in combination with lopinavir/ritonavir. However, there are 
yet no data on treatment with emtricitabine/tenofovir in 
patients with COVID-19. This clinical study is summarized 
in Table 2.
Oseltamivir
Oseltamivir (Tamiflu) is an anti-viral neuraminidase inhibi-
tor drug used for the treatment and prophylaxis of influenza 
A and B. Oseltamivir exerts its anti-viral activity by inhibi-
tion of the viral neuraminidase activity and viral replication. 
Oseltamivir seemed to suppress the virus reproduction in at 
least some cases [49, 72].
Coronaviruses are not known to utilize neuraminidase 
in viral replication; therefore, oseltamivir is unlikely to be 
of any therapeutic value. It was removed from the SARS-
CoV2 treatment protocol. The only study evaluating the 
effect of oseltamivir against coronaviruses showed it to be 
ineffective in preventing SARS-CoV1, even at high con-
centrations of the drug [73]. A retrospective, single-center 
case series of 138 hospitalized patients with SARS-CoV2 
pneumonia in Wuhan, China showed that in about 90% of 
patients who received oseltamivir, no effective outcome was 
reported [15]. A phase IV clinical trial of anti-viral drugs 
for SARS-CoV2 pneumonia is underway in Wuhan China 
(NCT04255017) [74]. In this study, the efficacy of three anti-
viral drugs (arbidol hydrochloride, oseltamivir, lopinavir/
ritonavir) is being evaluated and compared (Table 2). In a 
retrospective case series of 99 patients with SARS-CoV2 at 
a single center in Wuhan, 76% of patients received anti-viral 
treatment, including oseltamivir. At the time of evaluation, 
58% of patients remained hospitalized, 31% had been dis-
charged, and 11% had died [75].
Inhibitors of viral proteases
Lopinavir/ritonavir (LPV/r)
Lopinavir/ritonavir (Kaletra®), as the main protease inhibi-
tor, is mainly used for treating HIV infection [76]. Lopinavir/
ritonavir (LPV/r) is a combination of lopinavir and ribavirin 
and metabolized by the P450 cytochromes system in the 
liver. Because of the similarity in anti-viral activity between 
LPV/r and LPV alone, the effect of LPV/r is mainly driven 
by LPV [53, 77]. Pharmacokinetically, the CYP3A enzyme 
uses lopinavir as a substrate, but it is inhibited strongly by 
ritonavir (RTV). Since the enzyme activity of CYP3A can 
be affected by this drug, LPV/r should be cautiously used in 
combination with drugs that are metabolized by this enzyme 
[76]. Indeed, after inhibition of CYP3A by ritonavir, the 
serum concentration of LPV is increased [78].
SARS-CoV2 being an RNA virus like HIV [79], and also 
based on the clinical experiences in treating SARS-CoV1 
[80] and MERS [81], lopinavir/ritonavir was first proposed 
for managing SARS-CoV2 infection [76]. Using the molecu-
lar weight calculation tool, the molecular mass of protease 
can be calculated from the functional motif showing protease 
function within the sequence of the virus [82]. On this basis, 
the molecular mass of the relevant proteases for the HIV and 
SARS-CoV2 differs from each other and is 21.6 kDa and 
33.8 kDa, respectively. By standard comparison techniques 
[83], the required dosage of LPV/r for SARS-CoV2 infec-
tion was about 1.56-times higher than that for HIV infection. 
Hence, based on the modeling study, if lopinavir/ritonavir is 
used for the management of SARS-CoV2, a double dosage 
of that used for HIV infection is suggested [79]. Also, the 
ongoing clinical trials are all designed to evaluate the effi-
cacy of standard dosages of LPV/r in SARS-CoV2 patients.
The mechanism of LPV/r for treating coronavirus dis-
eases is still unclear. Since coronaviruses, including SARS-
CoV2, synthesize polyproteins followed by hydrolysis to 
maintain their structural and functional proteins [9, 84–86], 
it is suggested that LPV/r may block their multiplication 
cycle by inhibiting their proteases [87]. It is initially hypoth-
esized that lopinavir and ritonavir can inhibit the 3-chymo-
trypsin-like protease of SARS-CoV1 and MERS and may 
be associated with improvement of clinical outcomes in 
patients with COVID-19 in a non-randomized open-label 
trial [7]. However, more investigations are needed to find 
the inhibitory mechanism of HIV protease inhibitors on the 
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3-chymotrypsin-like and papain-like proteases of SARS-
CoV2 [10].
Molecular docking results showed that non-structural 
protein-3c (Nsp3c) or E-channel can serve as possible tar-
gets of ritonavir. Additionally, lopinavir’s possible targets 
include Nsp3b, helicase, and N-terminal receptor-binding 
domain (NRBD) [11]. It has also been shown that lopinavir 
and ritonavir produce strong interaction with the active site 
of SARS-CoV2 main protease (Mpro), in silico [88, 89].
Based on the prior research which has shown decreased 
mortality rates in patients with SARS-CoV1 infection by 
interferon-alpha (IFN-α) and lopinavir/ritonavir, the use of 
these medications is recommended by National Health Com-
mission of the People’s Republic of China [90]. Indeed, the 
earliest protease inhibitor combination that was introduced 
for the treatment of SARS-CoV2 was lopinavir/ritonavir. 
Because of its notably lower incidence of adverse outcomes 
in comparison with ribavirin alone, the efficacy of lopinavir/
ritonavir was documented in several studies. Moreover, the 
lower incidence of ARDS, nosocomial infection, and death 
were observed in combination therapy with ribavirin [91]. 
Preliminary reports have shown that patients infected with 
SARS-CoV2 and treated with lopinavir could achieve viral 
clearance [92]. Altogether, these data support the assump-
tion that some protease inhibitors may have an anti-viral 
effect by blocking the coronavirus main protease. Thus, 
based on its safety profile, LPV/r could be used as therapy 
and/or pre-exposure prophylaxis to reduce new infections 
by SARS-CoV2 [88].
D i f fe r e n t  c l i n i c a l  t r i a l s  ( fo r  ex a m p l e , 
ChiCTR2000029539) have been initiated to test protease 
inhibitors such as lopinavir/ritonavir in patients with 
SARS-CoV2 [10]. LPV/r was associated with the highest 
total number of planned inclusions and was tested in sev-
eral clinical trials. Furthermore, the use of this agent for the 
treatment of SARS-CoV2 has been described in case reports 
[89, 92] and a case series of patients infected with SARS-
CoV2 in Singapore [93]. Moreover, treatment by lopinavir/
ritonavir could significantly decrease the SARS-CoV2 viral 
loads in a Korean patient [92]. For investigation on LPV/r 
in patients with SARS-CoV2 infection, 9 clinical trials have 
been registered in China up to March 28, 2020 [78]. Sev-
eral trials involve lopinavir–ritonavir treatment (Table 2), as 
the standard care arm, in comparison with the use of other 
drugs for SARS-CoV2 such as arbidol, danoprevir–ritonavir, 
and interferon inhalation [94]. Nevertheless, a recent clini-
cal trial study on 199 patients with SARS-CoV2 infection 
showed that the treatment by lopinavir–ritonavir was not 
associated with clinical improvement in comparison with 
standard care procedures [95]. It appears that there have 
been some limitations in this study. First, it was not a blinded 
study; second, the delayed start of the treatment may attrib-
ute to the lack of effectiveness of LPV/r. Third, all patients 
enrolled in the study had an oxygen saturation (SaO2) of 
94% or less while they were breathing ambient air or a ratio 
of the partial pressure of oxygen (PaO2) to the fraction of 
inspired oxygen (FiO2) of less than 300 mmHg. Hence, 
future studies are needed to verify the efficacy of LPV/r 
anti-viral treatment. The wide availability and manufactur-
ing of lopinavir–ritonavir imply that it could be prescribed 
immediately for COVID-19. Several case reports and case 
series have used for this agent against SARS-CoV2. But, 
the trial results so far were disappointing [96]. Based on the 
direct inhibitory activity against viral replication, the detec-
tion of viral nucleic acid in patients has shown the inability 
of LPV/t to suppress the viral load. Thus, the whole effects 
of LPV/r were not simply observed, although some effects 
of the drug might be possible [96]. A clinical trial study on 
comparing favipiravir with lopinavir/ritonavir for the treat-
ment of SARS-CoV2 has shown that this drug had a more 
potent anti-viral activity with little adverse effects than that 
of lopinavir/ritonavir [50, 97].
There might be some explanations for the unexpected or 
lower effects of lopinavir–ritonavir. The patient selection in 
late phases of COVID-19 infection and also significant tissue 
damages (with considerable mortality in the control group) 
could be the main reasons for the inability of lopinavir–rito-
navir in whole treatments. In some cases, there is probable 
drug interference when LPV/r is used with other agents. 
Moreover, the drug concentration in the tissues where 
SARS-CoV2 is replicating is not detected and lopinavir 
could not have particular activity against SARS-CoV2. Inhi-
bition of viral replication is needed by the relatively higher 
concentration of lopinavir-ritonavir as compared with the 
serum levels found in patients treated with this drug [53, 96].
Nevertheless to the efficacy of LPV which is indicated in 
most of the data, the adverse reactions should also be con-
sidered [78]. Diarrhea, vomiting, and rash are the most com-
mon adverse reactions of LPV/r [98]. The most frequently 
reported adverse reactions in patients who received LPV 
were diarrhea, nausea, and asthenia [99]. The changes in 
laboratory findings included high levels of total bilirubin, 
triglyceride, and hepatic enzyme activities have also been 
reported [100, 101].
Darunavir
Darunavir (DRV), as the HIV protease inhibitor, can pre-
vent the formation of mature infectious virus particles by the 
selective inhibition of the cleavage of Gag-Pol polyprotein 
in virally infected cells [11].
In February 2020, the inhibitory effect of DRV on SARS-
CoV-2 infection was announced by Chinese researchers. Cell 
experiments indicated that the viral replication was signifi-
cantly inhibited by DRV at a concentration of 300 μM [50, 
102]. It has been shown that darunavir in combination with 
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Cobicistat (DRV/c) can significantly inhibit the replication 
of the SARS-CoV2 [91, 103]. This combination therapy 
was approved by the United States Food and Drug Admin-
istration (FDA) for the treatment of patients with AIDS. To 
enhance the pharmacokinetics and pharmacodynamics of 
darunavir, cobicistat, like ritonavir in LPV/r, can affect as 
a booster and inhibits the cytochrome P450 (CYP3A) [86, 
104]. In addition to in vitro and clinical trial studies, several 
in silico studies have also confirmed the effectiveness of the 
anti-viral activity of DRV against SARS-CoV2. The poten-
tial therapeutic effect of DRV against SARS-CoV2 may 
be mainly due to its inhibitory effect on papain-like viral 
protease (PLVP) and Main protease (Mpro) [11, 105–107]. 
DRV has been shown to display a high ligand affinity and 
a potential candidate, capable of disrupting communication 
between SARS-CoV2 receptor-binding domain and ACE2. 
Hence, DRV is now suggested to be repurposed for the treat-
ment of SARS-CoV2 infection for its possible disruption of 
cellular recognition, binding, and invasion. This drug has 
promising effects for an alteration of the viral tropism and 
the dynamics of human-to-human transmission when tested 
in a laboratory or clinical setting [108]. Clinical studies on 
the treatment of SARS-CoV2 by DRV are summarized in 
Table 2.
Danoprevir
Danoprevir is an investigational NS3/4A HCV protease 
inhibitor that had favorable effects against diverse HCV 
genotypes [109, 110]. Since the non-structural proteins, such 
as proteases, are essential for the pathogenicity of coronavi-
ruses, they serve as a good target for drug therapy [111]. It 
is proposed that the chymotrypsin-like protease of SARS-
CoV2 is structurally similar to other RNA viruses such as 
HCV [112, 113]. On the other hand, in a molecular dock-
ing simulation study, simeprevir has a stronger interaction 
with connecting receptors than lopinavir/ritonavir, which is 
commonly used in different SARS-CoV2 treatment regimens 
[114]. The anti-viral mechanism of simeprevir and dano-
previr is similar [115]. Recently, danoprevir was approved 
in China for the treatment of treatment-naive patients with 
non-cirrhotic genotype 1b chronic hepatitis C. It has also 
shown potent and broad-spectrum anti-viral effects on 
hepatitis C [116]. Moreover, in another molecular dock-
ing study, danoprevir has shown a potent inhibitory effect 
on SARS-CoV2 [107]. Therefore, it could be claimed that 
danoprevir can be a potential treatment in COVID-19. The 
efficacy of danoprevir has been confirmed for the treatment 
of hepatitis C and patients receiving this medication have 
been tolerated well [117]. There is a completed clinical trial 
(NCT04291729), which evaluated the efficacy of danoprevir 
combined with ritonavir in the treatment of COVID-19. The 
primary data reported from this clinical study demonstrated 
that all included patients had improved clinical and paraclin-
ical parameters. Fortunately, all of the included patients in 
this study were discharged from the hospital [118]. However, 
this study is an open-label clinical trial with low sample size, 
and another clinical trial with a larger sample size is ongo-
ing. While we can conclude that this treatment has some 
efficacy for the treatment of COVID-19 patients, further ran-
domized clinical trials are needed to confirm the result of 
the aforementioned study. The characteristics of this clinical 
trial have been reported in detail in Table 2.
Atazanavir
Atazanavir (ATV), with a mechanism of action of protease 
inhibition, is approved for treating HIV or AIDS [119]. As 
indicated in the preceding sections, non-structural proteins 
like protease, a critical enzyme for polyprotein process-
ing in CoVs [120], are necessary for the pathogenicity of 
CoVs [111]. Hence, atazanavir prevents the formation of a 
mature virus particle and inhibits SARS-CoV2 infection. In 
a study based on uncovering SARS-CoV2 helicase inhibi-
tors through molecular docking analysis, Borgio and co-
workers showed that atazanavir may interrupt the activity 
of SARS-CoV-2 helicase [121]. The recent study by Beck 
and his co-workersʼs based on molecule transformer-drug 
target interaction (MT-DTI) also showed that atazanavir 
was the best among the tested compounds for inhibitory 
SARS-CoV2 3C-like proteinase activity and the observed 
rankings was in the order of atazanavir > remdesivir > efa-
virens > ritonavir > dolutegravir [122]. A clinical trial 
(IRCT20100228003449N30) is also in the process of eval-
uating the efficacy and safety of hydroxychloroquine plus 
lopinavir or atazanavir/ritonavir combination in patients with 
COVID-19 (Table 2).
Cobicistat
Cobicistat is used in the treatment of HIV/AIDS and its main 
mechanism is via inhibition of human CYP3A proteins with 
also some limited effect on CYP2D6 [123]. Through inhi-
bition of the main protease, cobicistat is suggested to have 
potential in SARS-CoV2 therapy [124]. Since it is as effec-
tive as lopinavir/ritonavir for the treatment of HIV/AIDS and 
better tolerated due to its lower adverse effects (diarrhea 2% 
vs 27%), its effects in patients with SARS-CoV2 are being 
assessed under phase III clinical trial (NCT04304053). Cur-
rently, another clinical trial is in the process that investigates 
the effects of cobicistat in the treatment of pneumonia asso-
ciated with SARS-CoV2 (NCT04252274). The virological 
clearance rate of throat swabs, sputum, or lower respiratory 
tract secretions is being measured at day 7 of the treatment 
(Table 2).
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Noscapine
Terpenoids have numerous medicinal activities including 
anti-oxidant, anti-cancer, anti-bacterial, anti-inflammatory, 
and anti-viral effects through inhibition of virus proteases 
[125]. Noscapine (NOS) is a natural phthalideisoquinoline 
alkaloid that is extracted from the opium poppy, Papaver 
somniferum of the Papaveraceae family. It has been used for 
many years as a safe antitussive by suppressing the central 
nervous system [126, 127]. Kumar et al. have shown that 
the noscapine derivative (23B) could bind to the protease 
of SARS-COV2 effectively at 300 K and inhibit protease 
function based on computer-drug design studies through 
docking and molecular dynamic simulations. Furthermore, 
they showed 325 K was the best temperature for binding of 
the noscapine derivative with protease [128]. Currently, a 
clinical trial (IRCT20160625028622N1) is in the process 
that investigates the effects of noscapine on clinical and 
pulmonary manifestations of COVID-19 patients (Table 2).
Inhibitors of viral entry to the host cell
Chloroquine/hydroxychloroquine
The sulfate and phosphate salts of chloroquine (CQ) are 
categorized as anti-malarial drugs. Hydroxychloroquine 
(HCQ) is also used both as an anti-malarial drug and for 
autoimmune diseases such as rheumatoid arthritis and sys-
temic lupus erythematosus [129]. The proposed mechanism 
of anti-viral activity of CQ in SARS-CoV2 is via target-
ing endosomal low pH (acidification) needed for virus/
cell fusion, and interference with glycosylation of cellular 
receptors. Time-of-addition assay of CQ in Vero E6 cells 
showed anti-viral function at both entrances and post-entry 
steps of the infection with SARS-CoV2. The study by Wang 
et al. revealed that the 50% effective concentration  (EC50) 
of CQ was 1.13 μM and the  EC90 was 6.90 μM which rep-
resents desirable viral inhibition at micromolar concen-
trations. In addition to direct anti-viral activity, CQ/HCQ 
specifically targets the entry of extracellular zinc to intra-
cellular lysosomes where it interferes with RNA-depend-
ent RNA polymerase function and coronavirus replication 
[130]. Furthermore, the immunomodulatory effect of CQ 
increases its anti-viral activity in vivo [49], although the 
exact mechanism of action of CQ needs further studies. The 
molecular mechanism of HCQ is similar to CQ and it can 
inhibit the cytokine storm via suppressing T cell activation 
[131]. In vitro, HCQ was shown to be more potent than CQ 
against SARS-CoV2 [132]. CQ and HCQ have been shown 
to inhibit SARS-CoV-2 replication [133]. A study by Gao 
et al. involving more than 100 patients reported that CQ 
phosphate is more effective than the control treatment group, 
who were treated using standard treatment without CQ, in 
preventing the pneumonia exacerbation, improving lung 
function in computed tomography (CT) images, accelerat-
ing a viral seroconversion, and reducing the disease period 
with no serious side effects. Hence, this drug is recom-
mended for inclusion in the next version of the Guidelines 
for the Prevention, Diagnosis, and Treatment of Pneumonia 
Caused by SARS-CoV2 issued by the National Health Com-
mission of the People’s Republic of China [134]. Chinese 
experts recommend 500 mg CQ phosphate twice daily for 
10 days in patients with mild, moderate, and severe COVID-
19 pneumonia without contraindications to CQ [135]. One 
parallel, double-masked, randomized, phase IIb clinical trial 
suggests that the higher CQ dose regimen should not be 
recommended for critically ill COVID-19 patients because 
of its safety profile, especially when used concurrently with 
azithromycin and oseltamivir. This trial suffered from sev-
eral limitations such as small sample size, absence of a pla-
cebo control group, lack of exclusion criteria regarding the 
QTc interval (defined as the interval between Q wave and T 
wave in electrocardiogram) at baseline [136]. CQ is consid-
ered for SARS-CoV2 on a prophylaxis basis because of its 
potential efficacy, safety profile, convenient availability, and 
low cost. Two prophylactic programs were suggested for CQ 
against SARS-CoV2: (1) CQ 8 mg/kg/day for 3 days in post-
exposure, in asymptomatic cases must be taken during hours 
after well-known exposure, (2) for chronic prophylaxis in 
the outbreak or endemic areas, CQ 500 mg daily for 30 days 
and thereafter decreasing to 250 mg daily for as long as the 
threat of infection is diminished [137]. But to date, there is 
a lack of evidence to support the efficacy of CQ or HCQ in 
preventing COVID‐19 [138].
Different trial studies have shown that the use of HCQ 
in COVID-19 patients can improve clinical symptoms and 
patient survival [139, 140]. However, a study consisting of 
181 patients with COVID-19 pneumonia (84 receiving HCQ 
within 48 h of admission and 97 that did not) reported no 
difference in Intensive Care Unit (ICU) transfer or mortality 
within 7 days and did not support the use of HCQ in patients 
with COVID-19 pneumonia [141].
The rapid fall of nasopharyngeal viral load in COVID-
19 patients has been reported after they received HCQ and 
azithromycin combination therapy [142–144].
The most common side effects of HCQ and CQ are gastro-
intestinal effects such as vomiting and diarrhea [131]. Neu-
rologic side effects (including muscular weakness, diplopia, 
dyskinesia, seizures, myasthenic syndrome) and psychiatric 
side effects (including sleeplessness, agitation, psychosis, 
depression, anxiety, and confusion) have also been shown 
[145]. In long-term use, these drugs cause severe adverse 
effects including retinopathy and cardiomyopathy [131].
HCQ is generally less toxic, more soluble than CQ, and 
has lower tissue accumulation and adverse events than CQ. 
Also, HCQ can be recommended for pregnant women and is 
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cheaper and more readily available in many countries [131]. 
Furthermore, HCQ is preferred because of no interference 
with other anti-viral drugs such as oseltamivir, lopinavir/
ritonavir, ribavirin, interferons, and immunoglobulins [133]. 
On the other hand, COVID-19 patients are more vulnerable 
to side effects of CQ/HCQ because of their advanced age, 
co-morbidities including diabetes, obesity and cardiovascu-
lar disorder, and co-medication [145].
Because of the initial beneficial effect of CQ and HCQ in 
coronavirus diseases, several clinical trials on the efficacy of 
these drugs are currently ongoing. The officially registered 
clinical trials on these drugs are presented in Table 2. Of 
these, ten trials investigate their prophylactic effect against 
SARS-CoV2 in a healthcare setting or close contacts after 
exposure (Table 2). Because of insufficient clinical data and 
contradictory results, further well-designed clinical trials 
must be conducted for the suggestions of these drugs for the 
prevention or treatment of COVID-19 patients. Before using 
these drugs, the patients must also be having QTc. Also, 
long monitoring of side effects even after discontinuation of 
treatment due to prolong the half-life of CQ and HCQ must 
be performed. So, their off-label use outside of these trials 
is not recently recommended.
Arbidol
Arbidol (umifenovir), a small-molecular weight indole-
based molecule, has a broad-spectrum anti-viral activity 
against numerous DNA and RNA viruses. It has been shown 
that arbidol can inhibit influenza A and B and hepatitis C 
viruses entry into host cells by blocking viral fusion [146, 
147]. For prophylaxis and treatment of upper respiratory 
tract infections caused by influenza A and B viruses, arbidol 
has been approved in Russia and China [148]. Other stud-
ies also showed that arbidol hydrochloride can inhibit the 
fusion of the virus membrane to the host cells and block the 
virus replication [11]. In recent years, the effectiveness of 
arbidol against both SARS-CoV1 and MERS-CoV has been 
shown in many studies [11]. Due to a lack of significant 
adverse effects, arbidol is patented for SARS-CoV1 treat-
ment [147]. Since the anti-viral effects of arbidol against 
SARS-CoV1 have been confirmed in cell-based experi-
ments [149], it has been suggested to be a drug of choice 
for SARS-CoV2 treatment [17]. An in vitro study showed 
that arbidol can effectively inhibit SARS-CoV2 replication 
[71]. The dosage regimen of arbidol in adults with SARS-
CoV2 was recommended to be 0.2 g any time, twice daily, 
not to be administered over 10 days [150]. So far, the dos-
age regimen of arbidol in children with SARS-CoV2 has 
not been recommended [76]. It has been shown that arbidol 
may have effective inhibitory function against SARS-CoV2 
infection at the concentration of 10–30 μmol/L, and can also 
reduce the virus’s pathological effects in host cells [50, 102]. 
Molecular modeling studies have shown that some proteins 
of SARS-CoV2 such as spike, E-channel, Nsp7-Nsp8 com-
plex, Nsp14, and Nsp15 may interact with arbidol [11].
Several ongoing clinical trials are designed to evaluate 
the anti-viral efficiency of arbidol against SARS-CoV2 
(Table 2). Moreover, this drug has been used as arbidol 
hydrochloride with oseltamivir and LPVr, and also in com-
parison with lopinavir-ritonavir, and interferon-α-2a. Moreo-
ver, the arbidol and lopinavir/ritonavir (LPV/r) combination 
treatment has been compared with LPV/r alone in a retro-
spective cohort study on patients with SARS-CoV2. It was 
found that the desired clinical response in the arbidol–LPV/r 
combination group was better than LPV/r alone [151]. A 
randomized controlled study on treatment of SARS-CoV2 
by arbidol and Kaletra has also shown that arbidol could 
significantly reduce the incidence of severe SARS-CoV2 and 
had a better therapeutic effect [17].
There are some adverse reactions for arbidol therapy 
such as nausea, diarrhea, dizziness, and elevated serum 
aminotransferase. Moreover, arbidol should be administered 
with caution in patients with liver dysfunction because of 
its metabolism by the liver. Arbidol also can compete with 
high binding rate drugs to plasma proteins and increase the 
concentration of combined drugs, due to the 89.2–91.6% of 
protein-binding rate [76].
Baricitinib
Baricitinib is an anti-rheumatic medication for the treat-
ment of refractory rheumatoid arthritis [152]. The primary 
anti-inflammatory mechanism of baricitinib in rheumatoid 
arthritis is through inhibition of Janus kinase (JAK) enzymes 
[153]. In SARS-CoV2, however, baricitinib prevents viral 
entry into cells through different mechanisms. It inhibits 
AP2-associated protein kinase 1 (AAK1): an enzyme that 
promotes endocytosis of the virus. Additionally, baricitinib 
interferes with viral endocytosis through interaction with 
cyclin G-associated kinase (GAK). Baricitinib is also sug-
gested to reduce inflammation through inhibition of JAK1/2 
enzymes [154]. Accordingly, baricitinib may have positive 
clinical effects in COVID-19 patients and could be an alter-
native option for the treatment of COVID-19, especially 
in patients with concurrent rheumatoid arthritis disorder. 
However, the inhibition of JAK-STAT kinase by baricitinib 
interferes with the anti-viral activity of innate interferons 
[155]. Furthermore, baricitinib can produce some symptoms 
of upper respiratory tract infections, nausea, and thrombosis 
in rheumatoid arthritis patients receiving this medication. 
Therefore, the efficacy and safety of baricitinib in patients 
with COVID-19 infection is not yet apparent. At the time 
of writing this article, there are several registered clinical 
trials and observational studies on the efficacy and safety of 
baricitinib for the treatment of COVID-19. One of them is 
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completed and the primary outcome in this pilot study was 
the evaluation of baricitinib’s safety. It did not increase the 
risk of infections, cardiovascular, and hematologic adverse 
effects after 2 weeks of treatment. On the other hand, treat-
ment with baricitinib was associated with better clinical 
response and respiratory functions after 2 weeks of treat-
ment when compared with a baseline assessment [156]. 
Nevertheless, this study is an open-label, non-randomized 
clinical trial. To make a clinical decision on the efficacy 
and safety of this drug, we need further studies with larger 
sample sizes. The characteristics of registered clinical trials 
have been reported in detail in Table 2.
Ruxolitinib
JAK enzymes mediate signals from the cell surface receptors 
for various cytokines and growth factors that have a key role 
in inflammatory function. Ruxolitinib is a small molecule 
inhibitor of JAKs including JAK1 and JAK2 [157]. Among 
JAK inhibitors, ruxolitinib is currently used in patients who 
suffer myelofibrosis. In this hematological condition, rux-
olitinib can rapidly improve the patient’s quality of life by 
reducing the secretion of pro-inflammatory cytokines, such 
as IL-1, TNF-α, IFN-γ, and IL-6 [158–160].
Based on similar inhibitory function as baricitinib in 
blocking the viral clathrin-mediated endocytosis, Ruxoli-
tinib might probably be useful in COVID-19. Recently, 
Stebbing and colleagues reported the possibility of employ-
ing JAK1/2 inhibitors in COVID-19, with more focus on 
baricitinib, ruxolitinib, and fedratinib, due to their power-
ful anti-inflammatory action, but with also warning about 
their possible negative effects in the infection control [161]. 
Moreover, an adaptive Phase II/III clinical trial was con-
ducted, with a focus on the assessment of ruxolitinib’s safety 
in the first 20 participants (Phase II), followed by a much 
broader assessment of efficacy, while continuing to monitor 
safety, in an additional 60 participants (Phase III, total par-
ticipants across Phase II/III n = 80). Both phases are single-
arm, open-label, and occur at a single site at the University 
of Colorado Hospital. Study participants received 10 mg 
twice daily of ruxolitinib for 14 days and followed for up to 
29 days. Data from participants in this study would be com-
pared with data from other COVID-19 patients not receiving 
ruxolitinib (NCT04348071). It seems that ruxolitinib might 
lower the hyper inflammation caused by the virus, which 
would prevent damage to the lungs (e.g., ARDS) and pos-
sibly other organs.
Recombinant human ACE2
Recombinant human angiotensin-converting enzyme 2 
ACE2 (rhACE2) acts similarly to the ACE2 in the human 
body. It has the potential to treat ARDS for many reasons. 
During ARDS, the activation of the ACE causes vaso-
constriction in pulmonary vessels, causing a lung injury 
induced by hypoxia. Conversely, the activation of ACE2 
has a likely protective effect against lung damage in 
ARDS. Therefore, rhACE2 could act as a potential therapy 
for ARDS in different situations [162]. ARDS and multi-
organ dysfunction constitute significant complications 
in patients with COVID-19 infection. Therefore, the use 
of rhACE2 could be a practical approach in COVID-19 
patients with severe symptoms [163]. Unfortunately, there 
is yet no completed study on the efficacy and safety of this 
intervention. There are only two ongoing clinical trials on 
the efficacy of rhACE2 in the treatment of patients with 
COVID-19. The characteristics of registered clinical trials 
are described in detail in Table 2.
Bromhexine
Bromhexine is categorized as a mucolytic agent and is 
primarily used for bronchopulmonary infections with 
unusual mucous secretions. Previous studies have shown 
that it has some efficacy in respiratory infections. Bro-
mhexine causes a decrease in the severity of this infec-
tion by acting on mucus production, mucus clearance, and 
enhancement of anti-biotic penetration [164, 165]. The 
host proteases play an important role in the pathogenic-
ity of various viruses such as influenza viruses, Ebola 
viruses, and coronaviruses through different mechanisms 
[166]. In the case of coronaviruses, proteases probably 
serve as an activator of S-glycoprotein, which is a virus-
binding protein [167]. The trans-membrane protease serine 
2 (TMPRSS2) is a type of protease that is demonstrated 
to be pivotal for the pathogenicity of influenza viruses, 
SARS-CoV1, MERS, and other coronaviruses [167, 168]. 
Additionally, the structure of the target receptor of SARS-
CoV2 is approximately similar to SARS-CoV1 [169]. 
Accordingly, the TMPRSS2 is a probable target protease 
for SARS-CoV2 [167]. Therefore, inhibition of proteases, 
especially TMPRSS2, could slow down the rate of virus 
replication [170]. Bromhexine likely acts as an anti-viral 
drug through inhibition of TMPRSS2. However, there is 
no rationale in using bromhexine as monotherapy because 
of its adverse effects in high doses and lack of clinical 
evidence of its efficacy against SARS-CoV2 [170, 171]. 
Therefore, bromhexine could be an additional therapeutic 
option along with other anti-viral drugs. Up to now, there 
are three undergoing registered clinical trials on the safety 
and effectiveness of bromhexine in patients with suspected 
and mild COVID-19 infection. However, there is still no 
reported data on the efficacy of bromhexine in the treat-
ment of COVID-19. The characteristics of the registered 
clinical trials have been reported in detail in Table 2.




Interferons (IFN) can participate in the control of coronavi-
rus infection by enhancing the innate immune response [23]. 
Despite there is no evidence to validate the beneficial effects 
of passive immunization therapy, the use of interferon could 
theoretically be helpful for the treatment of viral infections 
[172]. To stimulate innate anti-viral responses in patients 
infected with SARS-CoV2, the administration of pegylated 
interferon-α-2a and 2b, which were approved for the treat-
ment of HBV and HCV, could be used. Despite the initiation 
of some clinical trial studies which used pegylated interferon 
plus an anti-viral nucleoside compound such as ribavirin, the 
synergistic activity against SARS-CoV2 is unclear. Evalu-
ating subcutaneous interferon therapies should be closely 
monitored because of multiple adverse effects. Thus, it may 
be required to reduce or discontinue therapy [17].
It has been shown that three virulence factors including 
Nsp1, Nsp3c, and ORF7a assist the escape of coronavirus 
from the host immune system by interfering with innate 
immunity. Studies have shown that Nsp1 has a specific deg-
radation activity on host mRNA by interacting with ribo-
somal small subunit and also can inhibit type-I interferon 
production [173, 174].
The effectiveness of synthetic recombinant IFNα in the 
treatment of SARS-CoV1 infected patients has been proven 
in clinical trials [175]. Therefore, the use of interferon in the 
treatment of SARS-CoV2 may have beneficial effects. Stud-
ies on evaluation of the effects of type-I interferon (IFN-I) on 
SARS-CoV1 infection were used as insights for recommend-
ing interferons for SARS-CoV2 infection. It is expected that 
SARS-CoV2 is sensitive to IFN-I pretreatment because of 
its similar viral replication kinetics to SARS-CoV1. Since 
IFNα-1b and 2b are subtypes of the IFN-I superfamily, the 
in vitro experimental effects of them might be shared by all 
other subtypes [176].
Different anti-virals such as interferon-α-1b/2b have 
been approved in the latest version of the guidelines for the 
treatment of SARS-CoV2 issued by NHC of the People’s 
Republic of China [177]. Patients with SARS-CoV2 are 
being recruited in randomized trials to evaluate the effi-
cacy of different anti-virals plus interferon-α. Some studies 
used interferon-α via aerosol inhalation for 2 weeks, while 
others used human recombinant interferon-α-1b (Cer-
rokin) using nebulization. Moreover, the administration 
of recombinant interferon-α-1b as an eye drop and nasal 
drop has been used in two studies (ChiCTR2000030480 
and ChiCTR2000029989). The recombinant super com-
pound interferon (rSIFN-co) has also been compared to 
interferon-α using nebulization (ChiCTR2000029638). 
Some studies claimed that ribavirin and interferon-α have a 
synergistic effect when applied at the early stage of SARS-
CoV2 infection. Health professionals were not fully satis-
fied yet, however, so further clinical research in this field 
is needed [31]. Evidence showed that the treatment using 
interferons, with or without ribavirin, and lopinavir/ritonavir 
are most likely to be beneficial against SARS-CoV2. The 
effectiveness of this treatment mainly depended on the tim-
ing of the treatment [91]. Moreover, some case reports used 
interferon therapy accompanied by other anti-virals for the 
treatment of patients with SARS-CoV2 [178–180].
Interferon‑beta (β)
Interferon-β is categorized as a type-I interferon and is the 
first and main drug approved for the treatment of relaps-
ing–remitting MS (RRMS) patients and it has two classes: 
interferon β-1a and interferon β-1b [181]. Interferons can 
increase the immune system in multiple ways, via anti-viral, 
anti-proliferative, immunomodulatory, and developmental 
activities [182]. The mechanism of action of the anti-viral 
activity of interferon-β is related to the activation of RNase 
that breaks down the nucleic acid chain of the virus. Also, it 
blocks the translation of RNA, prevents encapsidation, and 
viral release [183]. It seems that its administration at a later 
stage of COVID-19 might worsen the cytokine storm and 
exacerbate inflammation [184].
The synergistic inhibitory effect of ribavirin with 
interferon-β on replication of SARS-associated coronavirus 
has also been demonstrated in animal and human cell lines 
[185]. In a retrospective study on 256 patients with COVID-
19 pneumonia, interferon-β1b therapy was not associated 
with reducing in-hospital mortality. This study however 
suffered from several limitations including the retrospec-
tive design, selection and unmeasured confounding bias, 
and no evaluation of differences between the two groups in 
terms of virus elimination, and RT-PCR monitoring [183]. 
Furthermore, the effect of interferon-β1b as a combination 
therapy (with lopinavir, ritonavir + ribavirin) was investi-
gated in an open-label, randomized, phase II trial in COVID-
19 patients in Hong Kong. This combination therapy was 
safe and superior to lopinavir–ritonavir alone in reducing 
virus shedding, improving symptoms, and accelerating the 
discharge of patients with mild to moderate COVID-19. An 
important limitation of this study is open-label design, with-
out a placebo group, and confounded by a subgroup deleting 
interferon-β 1b within the combination group, depending 
on time from symptom onset [38]. The most common side 
effect of interferon-β is a flu-like syndrome (such as head-
ache, fever, and arthralgia). Other side effects of it include 
injection site reactions, depression, liver enzymes eleva-
tion, and hematologic abnormalities [186]. In eight Iranian 
clinical trials, the efficacy of interferon-β in COVID-19 in 
combination with conventional treatment is undergoing. 
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Furthermore, eight clinical trials registered in ClinicalTri-
als.gov explore the effects of interferon-β in COVID-19 
(Table 2). The outcomes of these trials will give insight 
into the promise of interferon-β for COVID-19 therapy. The 
effect of interferon-β in COVID-19 is unknown, but further 
phase III clinical trials with interferon β-1b as a basic treat-
ment with a placebo control group should be considered.
Programmed cell death 1 (PD‑1) blocking antibody
PD-1 blocking antibody is among a class of drugs that are 
commonly used for the immunotherapy of cancer. The 
mechanism of action is through blocking immune check-
point molecules. Recently, a PD-1 blocking antibody named 
“Nivolumab” was approved for the treatment of many can-
cers [187, 188]. On the other hand, the administration of the 
PD-1 blocking antibody in septic patients was associated 
with reversal of immune dysfunction due to infection, and 
it improved survival rate [189]. PD-1 is a specific marker 
on exhausted T cells during viral infections. As a result of 
the expression of PD-1 on cytotoxic T cells, the anti-viral 
activity of these cells diminishes in a variety of virus infec-
tions such as SARS-CoV2. Hence, blocking PD-1 with PD-1 
blocking antibodies would reverse T cell exhaustion in these 
patients [190]. The most adverse effects of PD-1 blocking 
antibodies in other indications were fatigue, pruritus, and 
diarrhea. Fortunately, most of the treatment-related adverse 
effects were low grade and tolerable [191]. Recently, a new 
RCT (NCT04268537) in China on the efficacy of the PD-1 
blocking antibody for the treatment of COVID-19 patients 
has been registered. The estimated participants in this RCT 
are 120 patients. To decide on the effect of this drug on the 
COVID-19, information from clinical studies is needed. The 
characteristics of a registered clinical trial are described in 
detail in Table 2.
Levamisole
Levamisole, a levisomer of tetramisole and belongs to the 
anti-helmintic class of medications and as the first mem-
ber of the new class of drugs which enhances the cellular 
immunity, is a synthetic low-molecular weight compound. 
Based on dosage and timing in clinical administration, both 
immunosuppressive and immunostimulatory functions are 
observed for levamisole [192]. According to a previous 
study, a combination of levamisole and ascorbic acid in vitro 
can reverse the depressed helper/inducer subpopulation of 
lymphocytes in measles. The abnormality in lymphocytes 
by levamisole could be reproduced by treating normal lym-
phocytes with measles virus in vitro. Therefore, levamisole 
could also be considered for the treatment of COVID-19 
[24, 193].
Common side effects of levamisole are mild and infre-
quent and include rash, gastrointestinal disorders (nausea, 
abdominal cramps, taste alteration), alopecia, arthralgia, flu-
like syndrome, and rarely agranulocytosis [194].
Heretofore, three randomized clinical trials are registered 
in Clinicaltrial.gov to evaluate the efficacy of the levami-
sole in the treatment of COVID-19. In the first double-blind, 
randomized, placebo-controlled phase II trial, the efficacy 
of oral levamisole and formoterol plus budesonide inhaler 
in combination with standard care was evaluated in the 
treatment of 30 patients with COVID-19 [195]. Two other 
Egyptian double-blind randomized placebo-controlled tri-




Over the past decades, the use of intravenous immuno-
globulin (IVIg) could improve the immunity and prognosis 
of severe infections by the immunomodulatory and anti-
inflammatory effects. Moreover, the cytokine storm could 
be inhibited by the use of IVIg [197]. Hence, IVIg therapy 
may improve the prognosis of critically ill patients with 
SARS-CoV2. The efficacy of IVIg therapy on 80 patients 
with severe SARS-CoV2 pneumonia is ongoing [122].
In a series of treatments including ribavirin, lopinavir and 
ritonavir, corticosteroids, type-I interferon, IVIg, or conva-
lescent plasma (CP), the effects of these treatments on the 
rate of morbidity and mortality in SARS-CoV1 patients, 
ARDS development in adult patients, and SARS-CoV1 
replication were investigated [198]. The immunomodula-
tory activity of convalescent plasma as well as IVIg therapy 
has been shown in studies [199]. This effect, as a treatment 
for SARS-CoV1 infection, has also reported in other Chi-
nese studies [200, 201]. In a study based on the clinical and 
epidemiological investigations of ten children with SARS-
CoV2 infection who had nonspecific symptoms, all patients 
were not required respiratory support or ICU and received 
anti-viral therapy with IFNα at admission. Despite becoming 
negative in the nasopharyngeal swab specimen test, the viral 
nucleic acid in the rectal swab was positive, even with medi-
cation [202]. Therefore, the treatment could not completely 
reverse the SARS-CoV2 infection.
The convalescent plasma containing neutralizing anti-
body titers above 1:640 at one dose of 200 mL was trans-
fused to ten patients with severe SARS-CoV2 infection who 
were under maximal supportive care and anti-viral agents. 
The primary outcome was the safety of CP transfusion. The 
improvement of clinical symptoms and laboratory param-
eters within 3 days after transfusion was also considered 
as the second outcome. The findings have shown that the 
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level of neutralizing antibody increased rapidly up to 1:640 
in five cases, while that of the other four cases maintained 
at a high level. Moreover, the clinical symptoms and the 
laboratory results, such as lymphocyte counts and C-reactive 
protein (CRP), were significantly improved. The viral load 
was undetectable after transfusion in seven patients who 
had previous viremia. Radiological findings showed vary-
ing degrees of absorption of lung lesions within 7 days. Due 
to the small sample size of this study, the clinical effective-
ness and optimal dosage/and time point of CP transfusion 
are needed further investigation in larger populations [203].
Fingolimod
Fingolimod (FTY720) is an oral immunomodulatory drug 
that inhibits lymphocytes through sphingosine-1 phos-
phate (S1P) receptors [204]. Fingolimod is the first FDA 
approved oral drug for the treatment of relapsing–remitting 
multiple sclerosis (RRMS). S1P down-modulation slows 
the lymphocytes egress from lymph nodes and its recircu-
lation can inhibit angiogenesis during inflammation. This 
drug can promote the endothelial barrier function and also 
regulates the B cells and dendritic cell migration [205]. The 
use of immune modulators along with ventilation support 
could prevent the development of ARDS in severe or critical 
patients with SARS-CoV2 according to some pathological 
findings of pulmonary edema and hyaline membrane forma-
tion [206].
Moreover, a prospective, non-randomized, no placebo-
controlled, phase II clinical trial to study the efficacy of the 
fingolimod in the treatment of COVID-19 was started by 
February 2020 in Fuzhou, China [207].
Thalidomide
Thalidomide is an immunomodulatory drug with its immu-
nologic effect varies under different conditions. Its effects 
can be related to the suppression of excessive TNF-α pro-
duction and down-regulation of selected cell surface adhe-
sion molecules involved in leukocyte migration. It has 
reported that the combination of thalidomide and celecoxib 
could improve severe pneumonia in SARS-CoV2 patients 
[208]. The drug suppresses the activation of NF-κB that pro-
motes the production of pro-inflammatory cytokines such as 
TNF-α and IL-8. It is thus suggested to benefit SARS-CoV2 
pneumonia [209].
Chen et al. reported a case of SARS-CoV2 pneumo-
nia successfully treated with thalidomide in combination 
with a low-dose glucocorticoid. Based on the results, they 
stated that thalidomide could be used to reduce oxygen con-
sumption and relieve digestive symptoms in SARS-CoV2 
patients. Also, thalidomide can be used as adjuvant therapy 
in COVID-19 patients [210].
Clinical trials of thalidomide treatment for SARS-CoV2 
pneumonia are underway in China (NCT04273529 and 
NCT04273581). The first study (NCT04273529) is a pro-
spective, multicenter, randomized, double-blind, placebo, 
parallel-controlled clinical study that evaluated the efficacy 
and safety of thalidomide in the adjuvant treatment of mod-
erate COVID-19 pneumonia (Table 2). Another study has 
been designed to evaluate the safety and efficacy of thalido-
mide combined with low-dose hormone adjuvant therapy for 
severe SARS-CoV2 patients (Table 2).
Immunosuppressive agents
Glucocorticoids
Corticosteroids are classic examples of immunosuppressive 
drugs. With their ability to stop or delay the progression of 
pneumonia, they have been proved to be effective for the 
treatment of ARDS [211, 212]. In addition to immunosup-
pressive activities, corticosteroids display potent anti-inflam-
matory properties with implications to reduce systemic 
inflammation, suppress exudative fluid in the lung tissues, 
promote absorption of the inflammasome, and prevent fur-
ther diffuse alveolar damage. Through these mechanisms, 
corticosteroids can relieve hypoxemia and effectively protect 
the lung by preventing further progression of respiratory 
insufficiency [213]. Furthermore, corticosteroids can reduce 
body temperature and help alleviate the poisoning symptom 
caused by hyperthermia [214]. During the SARS-CoV1 and 
MERS-CoV outbreak, it was shown that the administration 
of corticosteroids may be associated with some adverse 
outcomes such as delayed viral acid nucleic cease from the 
blood [199, 215–217]. Moreover, the association between 
systemic corticosteroid therapy with an increased mortality 
rate in these pulmonary diseases has been indicated [215, 
218]. Whether glucocorticoid therapy is definitively ben-
eficial in the clinical management of these two coronavirus 
infections is still being debated [216, 219–221].
Based on six studies on 574 patients with ARDS of any 
cause who received corticosteroid therapy, there is no suf-
ficient evidence to recommend this treatment [222].
According to the WHO and CDC (Centers for Disease 
Control and Prevention) recommendations, the corticos-
teroids should not be routinely utilized in the treatment of 
SARS-CoV2 unless other indications such as exacerbation 
of chronic obstructive pulmonary disease or septic shock 
exist [223].
Chinese reports revealed that many patients during the 
outbreak of SARS-CoV2 have received corticosteroid 
therapy. However, the available recommendations for the 
routine administration of corticosteroids are not sufficient 
[224, 225]. Because of the immediate clinical importance 
of harm or benefit from corticosteroids, further evidence 
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for or against corticosteroid therapy will be provided by the 
outcomes of ongoing clinical trial studies [224, 226, 227].
In patients with SARS-CoV2 who failed to respond to 
low-dose corticosteroid therapy, short-term moderate-dose 
corticosteroid plus immunoglobulin administration was 
effective for reversing the continued deterioration [228]. 
It is worth noting that there are some limitations to this 
study. First, the very small sample size (n = 10) was consid-
ered. Second, the moderate dosage of methylprednisolone 
(160 mg/day) is not recommended and the usage of steroids 
in pneumonia due to SARS-CoV2 is still controversial and 
being debated. The decreased risk of the mortality rate was 
reported in SARS-CoV2 patients who developed ARDS 
after treatment with methylprednisolone. So, the adminis-
tration of methylprednisolone may be beneficial for patients 
who develop ARDS [229]. Moreover, it has been recently 
reported that dexamethasone could reduce 28-day mortality 
in hospitalized patients who received respiratory supports 
(NCT04381936) [230].
Early diagnosis and timely treatment are critical for 
SARS-CoV2 infection. It is necessary to protect impor-
tant organs in infected patients with pneumonia and effec-
tive measures, such as corticosteroid treatment, should be 
considered to prevent the development of ARDS in severe 
patients [231]. In addition to the timing of treatment, it is 
also important to master the treatment duration and choose 
appropriate corticosteroid formulations and dosage. The 
basic principles of corticosteroid formulations selection lie 
in the following two aspects: a short half-life and strong 
penetrating ability. The corticosteroid formulation used in 
one study cohort for methylprednisolone was with a median 
effect half-life of 12–36 h, which has been proved to be asso-
ciated with a better intensity of immunosuppression [232].
There are insufficient data on the effectiveness of adjunc-
tive glucocorticoid therapy in SARS-CoV2-infected patients 
with severe lower respiratory tract infections [233]. Based 
on the available evidence, the proper use of low-dose cor-
ticosteroids may provide survival advantages for critically 
ill patients with SARS-CoV2. However, this treatment 
in patients with refractory ARDS, sepsis, or septic shock 
should be strictly performed according to the recommended 
guidelines. For clinical management of critically ill patients 
with SARS-CoV2, the low-dose and short-time corticoster-
oids therapy (methylprednisolone, < 1 mg/kg body weight, 
no more than 7 days), besides the adverse reaction monitor-
ing, would be more beneficial. Moreover, due to the delayed 
adverse effects in these patients, it is essential to perform 
long-term follow-up (6 months–3 years) studies [234].
The systemic corticosteroid treatment along with anti-
viral agents including neuraminidase inhibitors (oseltami-
vir, peramivir, zanamivir, etc.), ganciclovir, acyclovir, and 
ribavirin, as well as methylprednisolone, which have recom-
mended previously in clinical practice for the treatment of 
influenza virus [15, 24], are invalid for SARS-CoV2 and, 
thus, not recommended [8]. Corticosteroid therapy for the 
treatment of SARS-CoV2-induced lung injury or shock has 
not been recommended [224].
The systemic steroids should not be used for children with 
SARS-CoV2. Since there is not significant lung inflamma-
tion in children with SARS-CoV2, immunomodulation is 
not required. However, corticosteroid therapy may be useful 
when children require ventilation and develop ARDS [229]; 
although the beneficial effects of this treatment are not con-
sistent and accurate [235].
An in vitro study has shown that ciclesonide, like an 
inhaled corticosteroid, can suppress SARS-CoV2 replica-
tion in cultured cells at low concentrations and the  EC90 
was 6.3 μM. Ciclesonide also exhibited low cytotoxicity 
and potently suppressed viral replication. Mutation analysis 
has shown that non-structural protein-15 (NSP15) can be 
resistant to ciclesonide. This observation suggests that the 
effect of ciclesonide was specific to coronavirus, and it may, 
thus, be a candidate drug for the treatment of SARS-CoV2 
infection. In comparison with ciclesonide, other corticoster-
oids including cortisone and prednisolone, which are com-
monly used for systemic steroid treatment, have been tested 
against SARS-CoV2. Viral replication was not suppressed 
by dexamethasone and fluticasone [236]. High concentra-
tions of ciclesonide can be administered to infants, because 
of its safety. Since ciclesonide does not significantly enter 
the bloodstream and remains in the lung tissue, ciclesonide 
inhalation can reduce viral replication and host inflamma-
tion in the lungs. Hence, the evaluation of ciclesonide with 
consideration of the balance between its benefit and risk 




Evidence has shown that patients with COVID-19 who 
were hospitalized in ICU had higher levels of plasma 
cytokines such as TNF-α, granulocyte-colony stimulating 
factor (G-CSF), monocyte chemoattractant protein (MCP1), 
macrophage inflammatory protein 1α (MIP1α), interferon-
γ-inducible protein (IP10) and several interleukins includ-
ing IL-6, IL-2, IL-7, and IL-10 [75, 217]. It is suggested 
that IL-6 plays an important role in the cytokine storm and 
drugs that target this cytokine are good treatment options for 
severe and critically ill COVID-19 patients. Tocilizumab, as 
a recombinant humanized anti-human IL-6 receptor mono-
clonal antibody, is mostly used in the treatment of rheuma-
toid arthritis. Via binding to sIL-6R (soluble form of IL-6 
receptor) and mIL-6R (membrane-bound IL-6 receptor), it 
can inhibit the IL-6 signal transduction [237].
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Tocilizumab is currently approved by the US FDA for 
the treatment of severe cytokine release syndrome (CRS) 
in addition to idiopathic arthritis, rheumatoid arthritis, and 
giant cell arteritis [238]. Several case report studies have 
been shown that tocilizumab improved some clinical symp-
toms in COVID-19 patients [239–244]. A pilot prospective 
open, single-arm multicenter study on off-label use of toci-
lizumab in 63 severe COVID-19 patients revealed improve-
ment in respiratory and laboratory parameters [245].
The efficacy of tocilizumab for SARS-CoV2 was inves-
tigated in 20 severe or critically ill COVID-19 patients who 
received the drug in addition to conventional therapy. After 
a few days, the fever and other symptoms were shown to be 
improved significantly [246].
In one study, the impact of low-dose tocilizumab was 
assessed on mortality rate in 85 patients with COVID-19 
related pneumonia and respiratory failure. Patients in the 
tocilizumab group revealed a significantly more survival 
rate than control patients. The important limitation of this 
study is the lack of a randomized double-blind approach 
[247]. Also, a study in a single academic medical center in 
the U.S. did not report significant clinical improvement in 
temperature or oxygen needs in most of the patients treated 
with tocilizumab. These data suggest that caution needs 
to be taken when using tocilizumab in severe COVID-19 
patients [248].
Adverse effects of long-course treatment with tocilizumab 
consist of serious infections (such as pneumonia, urinary 
tract infection, cellulitis, etc.), gastrointestinal perforations, 
infusion reactions (such as hypertension, headache, and skin 
reactions), anaphylaxis, thrombocytopenia, elevated liver 
enzymes, and elevated lipid profile [238]. Adverse effects 
observed with tocilizumab use in patients with COVID-19 
are also recorded [249, 250]. The safety and efficacy of sub-
cutaneous tocilizumab have been reported in a case series of 
patients with COVID-19 pneumonia. No significant adverse 
effects were seen except for a mild increase in the level of 
liver enzymes two days after administration with subsequent 
immediate normalization. Indeed, radiological findings and 
clinical symptoms were improved.[251].
Tocilizumab has been recommended for COVID-19 treat-
ment in the Diagnosis and Treatment Protocol for Novel 
Coronavirus Pneumonia (Trial Version 7) promulgated by 
the Chinese government [252]. Also, thirty-two trials are 
currently evaluating the efficacy of tocilizumab for COVID-
19 (Table 2). Further controlled trial studies will be needed 
to clarify the true clinical effect of this IL-6-blocking ther-
apy on COVID-19 infection and to determine optimal patient 
selection and timing for the use of tocilizumab during the 
disease process. Beyond proving its efficacy and above-men-
tioned side effects, it has several limitations such as being an 
expensive drug that can only be administered intravenously. 
So, more attention must be considered in future studies 
including the comparison of different dosages and modes 
of administration.
Sarilumab
Sarilumab (Kevzara®) is an IL-6 receptor antagonist and 
has FDA approval in moderately to severely active rheuma-
toid arthritis adults who have inadequate response or intol-
erance to one or more disease-modifying anti-rheumatic 
drugs [253]. It has the potential to treat COVID-19 given 
the important role of IL-6 in the cytokine storm [254]. It 
binds to soluble and membrane-bound IL-6 receptors. 
Because of the unavailability of IL-6 level measurements in 
most institutions, CRP levels may be useful for monitoring 
the response to therapy [143]. One ongoing randomized, 
double-blind, placebo-controlled study is comparing the 
effect of sarilumab higher dose (400 mg), sarilumab lower 
dose (200 mg), and placebo on 400 patients with COVID-19. 
Preliminary results from the phase II portion of an ongo-
ing phase II/III sarilumab trial (NCT04315298) suggest that 
sarilumab can lower CRP in comparison to placebo. Also, 
sarilumab did not show a beneficial effect on the clinical 
outcomes of patients in “severe” disease [255]. Because of 
the lack of evidence for efficacy and safety of sarilumab in 
COVID-19 patients, this drug is not recommended currently. 
The clinical efficacy of sarilumab is being investigated in 
eight clinical trials which are illustrated in Table 2.
Siltuximab
Siltuximab (CNTO 328) is a monoclonal antibody–drug 
conjugate to interleukin-6 (IL-6), so it neutralizes IL-6 
bioactivity. It also promotes tumor cell death and approved 
for the treatment of some viral diseases like HIV, human 
herpesvirus-8 (HHV-8), multicentric Castleman’s dis-
ease (MCD), multiple myeloma (MM), myelodysplastic 
syndrome (MDS), prostate cancer, ovarian cancer, lung 
cancer and decrease anorexia and cachexia that related to 
cancer [256–258]. Siltuximab enhances cytochrome P450 
activity and decreases the levels of TNF-α, IL-1, CCL2, 
CXCL12, and VEGF [259, 260]. Currently, three studies 
(NCT04329650, NCT04322188, and NCT04330638) are 
investigating the effects of siltuximab on COVID-19 infec-
tions (Table 2).
Eculizumab
Eculizumab (Soliris®) is a humanized monoclonal anti-
body that is commonly administered for the treatment of 
complement-mediated diseases [261, 262]. The primary 
mechanism of eculizumab in these diseases is blocking the 
cleavage of complement protein C5 into C5a and C5b [262]. 
Both C5a and C5b have pro-inflammatory effects. Therefore, 
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inflammation and cell damages would be decreased by sup-
pressing the activity of this complement cascade [262]. 
Additionally, complement activity is associated with more 
progressing damage in patients with SARS-CoV-2 infection 
[263, 264]. Based on the anti-complement mechanism of 
eculizumab, it is suggested to be an effective treatment for 
SARS-CoV2. However, despite its clinical usefulness, ecu-
lizumab increased the risk of some infections, especially 
meningococcal infection, even with prior vaccination [262, 
265]. Therefore, a more conservative approach should be 
considered while we use this medication. In a case series 
study, four patients with severe pneumonia and ARDS were 
admitted and received eculizumab up to four doses along 
with standard treatment (lopinavir–ritonavir + hydroxy-
chloroquine). All of the patients got better clinically and the 
treatment with eculizumab caused a reduction in inflamma-
tory markers such as CRP [266]. The result of this study sug-
gests the probable efficacy of eculizumab for the treatment 
of patients with pneumonia due to SARS-CoV2. To confirm 
the results of this study, some registered trials are ongoing. 
The selected doses of eculizumab in these studies are similar 
to other indications and are detailed in Table 2.
Tetrandrine
Tetrandrine (Tet) is a major alkaloid isolated from the roots 
of Stephania tetrandrae S. Moor of the Menispermaceae 
family. It has inhibitory effects on asthma, anti-allergic, 
anti-inflammatory, anti-oxidant, anti-fibrogenic activities, 
immunomodulation, and inhibition of platelet aggregation. 
Tetrandrine can improve the pulmonary function and struc-
ture by different mechanisms, including the modification 
of calcium metabolism in many cell types. Tetrandrine has 
potent inhibitory effects on IL-5 and IL-6 and prevents the 
production of IL-1. It has been reported that tetrandrine, as a 
nonspecific calcium channel blocker (CCB), has anti-inflam-
matory action through inhibition of 5-lipoxygenase [267, 
268]. Tetrandrine with multiple mechanisms is also able to 
inhibit fibroblasts and pulmonary fibrosis. So, it may help 
improve lung function in COVID-19 patients. Currently, a 
clinical trial (NCT04308317) is in the process that investi-
gates the effects of tetrandrine on pneumonia associated with 
COVID-19 (Table 2).
NSAIDs
Nonsteroidal anti-inflammatory drugs (NSAIDs) decrease 
lipid mediators, including leukotrienes, prostaglandins, and 
platelet-activating factors. Arachidonic acid is a precursor 
for the biosynthesis of leukotrienes and prostaglandins while 
lysophospholipid is the starting material for the synthesis 
of platelet-activating factor. Prostaglandins are products 
of cyclooxygenase-1 (COX-1) and COX-2; these enzymes 
are blocked by aspirin and ibuprofen. Because most pro-
inflammatory prostaglandins are products of COX-2, a 
selective COX-2 inhibitor such as celecoxib is the preferred 
anti-inflammatory agent. Although NSAIDs have some side 
effects, they are valuable drugs for treating life-threatening 
conditions, such as wet lungs [269].
Altogether, there are limited studies that investigate the 
effectiveness of NSAIDs on SARS-CoV2-associated pneu-
monia. Moreover, the role of NSAIDs during viral infections 
is still controversial. In vivo study showed that ibuprofen 
could induce overexpression of ACE2 [17]. This effect may 
theoretically increase susceptibility to SARS-CoV2 and also 
can worsen the clinical outcomes during COVID-19 [270]. 
Moreover, masking off the fever rises during SARS-CoV2, 
delaying in the laboratory diagnosis, and improper manage-
ment of the infection may occur when using both NSAIDs 
and paracetamol (acetaminophen) [18]. Despite the effects 
of paracetamol as the first line of anti-pyretic drugs, some 
unverified reports exist on ibuprofen treatment in severe 
cases of SARS-CoV2 [9]. However, the administration of 
ibuprofen in children with poor fluid intake or suspected 
acute kidney injury is recommended to be avoided [235].
Pulmonary vaso‑effectors
Nitric oxide
Nitric oxide (NO) is a selective pulmonary vasodilator gas 
used as rescue therapy in refractory hypoxemia due to ARDS 
[271]. Various ventilation methods, inhaled nitric oxide gas 
(iNO), surfactants, and extracorporeal life support cannot 
be used for every patient, because no evidence-based data 
exist [272]. In clinical settings, NO gas has been approved 
by the FDA for the treatment of pulmonary hypertension of 
the newborn in the presence of hypoxic respiratory failure. 
The NO gas has also been advocated as a rescue treatment 
in adults with hypoxic ARDS [273]. The reaction of NO 
with oxygen to form  NO2 may cause inflammation in lung 
tissues. Moreover, oxidation of ferrous hemoglobin (Hb) to 
methemoglobin (Met-Hb) by NO could reduce the oxygen 
transport and its release to tissues [274]. By carefully moni-
toring NO/NO2 delivery and Met-Hb levels, the risk of iNO 
administration at 80 ppm for 24 h can be minimal according 
to the FDA reports [275]. It has been shown in vitro and 
clinical studies that iNO has anti-viral activity against other 
strains of coronavirus [271]. The increased survival rate of 
infected eukaryotic cells by SARS-CoV1 using S-nitroso-
N-acetylpenicillamine, as a NO donor, has shown the anti-
viral potential of NO [276]. Moreover, the use of iNO in 
patients with SARS-CoV1 who had severe symptoms could 
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improve the severe hypoxemia and pulmonary hypertension, 
and shortened the time of ventilation support [276].
The very similar genomic identity of SARS-CoV1 to the 
SARS-CoV2 virus indicates the potential effectiveness of 
iNO therapy in patients with SARS-CoV2 [271].
Currently, some RCT studies are studying the effective-
ness of iNO in mechanically ventilated patients with SARS-
CoV2 infection and some clinical improvements have also 
been seen in primary reports [271, 277].
Sildenafil
By inhibiting type 5 phosphodiesterase (PDE), silde-
nafil (Viagra®) increases the level of cyclic guanosine 
monophosphate (cGMP) and induces vasodilatory effects 
in the pulmonary vasculature. Thus, it has FDA approval 
for the treatment of pulmonary arterial hypertension (PAH) 
in adults [278, 279].
According to the clinical trial study outlined in Table 2, a 
pilot study on the efficacy and safety of sildenafil citrate in 
ten patients with SARS-CoV2 infection is in progress [191]. 
No clear data are showing the effectiveness of sildenafil for 
COVID-19 until now.
Aviptadil
Aviptadil (VAP) is a synthetic vasoactive intestinal poly-
peptide (VIP), a synthetic form of the 28-amino-acid VIP, 
which increases the activity of adenosine cyclase. It causes 
cavernosal smooth muscle relaxation with a subsequent fill-
ing of cavernosal sinuses and erection [280].
Aviptadil reduces the right heart strain by acting as a 
weak pulmonary vasodilator. Moreover, it plays a role in 
the improvement of the oxygenation in patients with chronic 
lung disease and also can participate in a modest and short-
lived pulmonary vasodilation induction without affecting 
systemic blood pressure [281]. Currently, two randomized 
clinical trials (NCT04311697 and NCT04360096) are in 
process that investigates the effects of aviptadil on acute 
lung injury, ARDS, and dyspnea associated with COVID-19 
(Table 2). So, aviptadil might have an application in SARS-
CoV2 patients to improve lung function.
Bevacizumab
Bevacizumab (Avastin) is a humanized anti-VEGF (vascular 
endothelial growth factor) monoclonal antibody. Evidence 
has shown higher VEGF levels in patients with SARS-
CoV2. VEGF acts as an angiogenic inducer in vivo, so that 
bevacizumab by inhibiting VEGF can decrease the VEGF 
level caused by the up-regulation of the infected respiratory 
tract epithelium, severe inflammation, and hypoxia, all of 
which can decrease vascular permeability and pulmonary 
edema in patients with SARS-CoV2 [94, 282].
A pilot study of bevacizumab in the treatment of severe 
or critical Chinese patients with SARS-CoV2 pneumonia 
started in February 2020. Patients with SARS-CoV2 under 
ECG monitoring were given bevacizumab injection 500 mg 
plus normal saline (NS) 100 ml, time is no less than 90 min. 
PaO2/FiO2 ratio at the times of 24 h, 72 h, and 7 days is the 
main outcome of this pilot study [283]. In another multi-
center triple-blind randomized placebo-controlled trial, the 
efficacy and safety of bevacizumab in 140 critical patients 
with SARS-CoV2 are evaluated in Qilu Hospital of Shan-
dong University, China. Patients in the intervention group 
received bevacizumab 7.5  mg/kg body weight plus NS 
100 ml. The time from randomization to an improvement 
of two points on a seven-category ordinal scale or live dis-
charge from the hospital is considered as the main outcome 
[284].
Losartan
Losartan is an angiotensin II receptor antagonist that is used 
to treat hypertension and to slow long-term kidney damage 
in people with type 2 diabetes who also have high blood 
pressure. ACE2 has been identified as a host cell receptor 
that binds to viral surface proteins leading to infection [46]. 
Overactivation of ACE–AngII–AT1 caused by COVID-19 
infection can lead to acute lung fibrosis. ACE2 has a deter-
minant anti-fibrotic role in lung injury induced by sepsis, 
acid aspiration, SARS-CoV1, paraquat poisoning, and lethal 
avian influenza. The ACE–AngII–AT1 axis is also known as 
a molecular pathway for end-organ damage. Losartan may, 
thus, be suggested as a potential drug to protect lung fibrosis 
induced by coronavirus [285]. Currently, two clinical trials 
are in signs of progress that are investigating the beneficial 
effects of losartan in SARS-CoV2 infection compared to 
placebo (NCT04312009 and NCT04311177). In another 
case–control study, the effects of ACE-I and/or ARB drugs 
on the treatment of coronavirus disease are to be surveyed 
in 5000 patients (NCT04318418) (Table 2).
Others
Carrimycin
Carrimycin is an anti-mycobacterium drug used for treat-
ing tuberculosis especially in cases of drug resistance [286]. 
No clear data are showing the application of carrimycin for 
SARS-CoV2 infection until now. The efficacy and safety 
of carrimycin treatment in 520 patients with SARS-CoV2 
are currently in progress as the multicenter, randomized, 
and open-controlled clinical trial study (NCT04286503, 
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Table 2). The reversing of the fever to normal, resolving 
the pulmonary inflammation, and reduced SARS-CoV2 
RNA levels at the end of treatment are the main primary 
outcomes.
Mepolizumab
Mepolizumab is a fully humanized IgG1κ monoclonal anti-
body that has affinity and selectivity to IL-5, thereby inhibit-
ing ligand binding and decreasing peripheral blood eosino-
phils in humans. It is approved as an add-on therapy for 
patients with uncontrolled severe eosinophilic asthma [287]. 
Its potential for SARS-CoV2 is yet to be demonstrated.
Conclusion
The global pandemic of SARS-CoV2 in the face of a lack of 
effective prevention and therapeutic measures resulted in sig-
nificant morbidity and mortality of the disease. Some clini-
cal studies on conventional anti-viral therapies have been 
conducted around the world so far but the results remain 
to be controversial. In general, the selection of appropriate 
treatment for patients with COVID-19 depends on differ-
ent factors, including the stage of the disease and its symp-
toms. Due to the differences in individual genetics in drug 
metabolism as well as the diversity of immune responses to 
the coronavirus, prescribing drugs among different patient 
populations may also be a challenge. Therefore, consider-
ing personalized medicine to select the best treatment along 
with an effective dose with minimal side effects would be a 
rational consideration in the future. Various studies are cur-
rently underway to evaluate vaccines against SARS-CoV2. 
However, due to genetic changes in the viral nucleic acid 
among different hosts, these specific vaccines may not have a 
definite preventive effect. Several therapies, which are ongo-
ing by different clinical trial studies from January 2020 until 
now, can help to find more efficient treatment against SARS-
CoV2 with minimal side effects. Moreover, structural and 
molecular docking studies on virus proteins and different 
drug candidates may also play an important role in find-
ing the specific target for therapeutic agents. Because of the 
contradictory benefit of anti-viral agents for COVID-19, the 
efficacy of drugs mostly was evaluated as the combination 
therapy. In the current condition, it seems that combination 
therapy of anti-viral drugs, including viral RNA polymer-
ase inhibitors (such as remdesivir), viral protease inhibitors 
(such as atazanavir), blockers of virus entry to the host cell 
(such as arbidol), and immune system modulators (such as 
IVIg), as well as the use of supplement therapy (such as 
melatonin and vitamin D) can be recommended for effective 
control of COVID-19. Therefore, it is necessary to strive for 
developing specific drug/treatment and or vaccine, reduce 
the morbidity and mortality of SARS-CoV2 infection and 
establish scientific capabilities to rapidly diagnose and treat 
new viruses in the future.
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